Unnamed: 0,title,date,stock,sentiment
1179115.0,Surmodics Receives CE Mark For Its SurVeil Drug Coated Balloon,2020-06-08 08:36:00-04:00,SRDX,neutral
1179116.0,"Surmodics Q2 EPS $0.040 May Not Compare To $(0.110) Estimate, Sales $22.800M Beat $20.840M Estimate",2020-04-29 16:13:00-04:00,SRDX,neutral
1179117.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,SRDX,positive
1179118.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,SRDX,negative
1179119.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,SRDX,neutral
1179120.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,SRDX,neutral
1179121.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,SRDX,negative
1179122.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,SRDX,negative
1179123.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,SRDX,negative
1179124.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-11 11:41:00-04:00,SRDX,negative
1179125.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,SRDX,positive
1179126.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,SRDX,negative
1179127.0,Stocks That Hit 52-Week Lows On Friday,2020-03-06 11:22:00-05:00,SRDX,negative
1179128.0,"The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study",2020-03-06 08:49:00-05:00,SRDX,negative
1179129.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-05 10:29:00-05:00,SRDX,negative
1179130.0,"The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies",2020-03-04 07:37:00-05:00,SRDX,negative
1179131.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,SRDX,negative
1179132.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,SRDX,neutral
1179133.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,SRDX,negative
1179134.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-20 10:54:00-05:00,SRDX,negative
1179135.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,SRDX,negative
1179136.0,"Surmodics Q1 EPS $0.05 Beats $(0.08) Estimate, Sales $22.616M Beat $22.08M Estimate",2020-02-05 16:28:00-05:00,SRDX,neutral
1179137.0,"The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data",2020-02-05 07:43:00-05:00,SRDX,neutral
1179138.0,"The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus",2020-02-02 13:04:00-05:00,SRDX,neutral
1179139.0,"Benzinga's Top Upgrades, Downgrades For December 11, 2019",2019-12-11 10:46:00-05:00,SRDX,positive
1179140.0,Needham Downgrades Surmodics to Hold,2019-12-11 06:25:00-05:00,SRDX,neutral
1179141.0,58 Biggest Movers From Friday,2019-11-04 07:12:00-05:00,SRDX,neutral
1179142.0,50 Stocks Moving In Friday's Mid-Day Session,2019-11-01 13:09:00-04:00,SRDX,neutral
1179143.0,"Benzinga's Top Upgrades, Downgrades For Npvember 1, 2019",2019-11-01 09:45:00-04:00,SRDX,positive
1179144.0,Lake Street Downgrades Surmodics to Hold,2019-11-01 09:03:00-04:00,SRDX,neutral
1179145.0,"Surmodics Sees FY20 EPS Guidance $(0.60)-$(0.30) Vs. $0.51 Est., Sales $87M-$91M Vs. 104.8M Est.",2019-10-31 16:23:00-04:00,SRDX,neutral
1179146.0,"Surmodics Q4 EPS $0.37 Up From $0.05 YoY, Sales $30.8M Up From $23.038M YoY",2019-10-31 16:20:00-04:00,SRDX,neutral
1179147.0,Surmodics Reports Sundance Sirolimus-Coated Balloon Catheter Wins FDA Breakthrough Device Status,2019-10-29 08:32:00-04:00,SRDX,positive
1179148.0,Surmodics Completes Enrollment In Pivotal TRANSCEND Clinical Trial,2019-08-28 08:31:00-04:00,SRDX,neutral
1179149.0,100 Biggest Movers From Yesterday,2019-08-02 05:53:00-04:00,SRDX,neutral
1179150.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,SRDX,negative
1179151.0,28 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-01 04:20:00-04:00,SRDX,neutral
1179152.0,"The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster",2019-07-31 07:06:00-04:00,SRDX,negative
1179153.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,SRDX,negative
1179154.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,SRDX,negative
1179155.0,"SurModics Q2 EPS $0.07 Beats $(0.02) Estimate, Sales $22.676M Beat $22.03M Estimate",2019-05-01 17:35:00-04:00,SRDX,neutral
1179156.0,"The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue",2019-05-01 07:39:00-04:00,SRDX,neutral
1179157.0,Surmodics Reports Its Sublime Guide Sheath Received FDA 510(k) Approval,2019-04-23 08:33:00-04:00,SRDX,positive
1179158.0,Surmodics Offers Update Related To TRANSCEND Trial,2019-04-17 11:04:00-04:00,SRDX,neutral
1179159.0,Surmodics Says it is Assessing the Impact From an FDA Communication on the Potential for Increased Mortality After Use of Paclitaxel-Coated Balloons On its TRANSCEND Clinical Trial,2019-03-18 08:13:00-04:00,SRDX,positive
1179160.0,60 Biggest Movers From Friday,2019-02-04 05:05:00-05:00,SRDX,neutral
1179161.0,45 Stocks Moving In Friday's Mid-Day Session,2019-02-01 12:34:00-05:00,SRDX,neutral
1179162.0,64 Biggest Movers From Yesterday,2019-02-01 05:00:00-05:00,SRDX,neutral
1179163.0,48 Stocks Moving In Thursday's Mid-Day Session,2019-01-31 12:16:00-05:00,SRDX,neutral
1179164.0,"The Daily Biotech Pulse: Hologic, Celgene Earnings, FDA To Rule On Alkermes Depression Drug",2019-01-31 09:01:00-05:00,SRDX,negative
1179165.0,"Surmodics Narrows FY19 Sales Guidance From $92M-$97M To $94M-$97M vs $93.8M Estimate, Adj. EPS From $(0.07)-$0.23 To $0.02-$0.22 vs $0.09 Est.",2019-01-30 16:35:00-05:00,SRDX,neutral
1179166.0,"SurModics Q1 EPS $0.12 Up From $0.10 YoY, Sales $22.241M Beat $20.18M Estimate",2019-01-30 16:34:00-05:00,SRDX,neutral
1179167.0,"The Daily Biotech Pulse: Roche Scraps Alzheimer's Disease Trials, Amgen Issues Weak Guidance",2019-01-30 08:12:00-05:00,SRDX,negative
1179168.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2019-01-27 16:07:00-05:00,SRDX,neutral
1179169.0,"SurModics Sees FY19 Adj. EPS $(0.07)-$0.23 vs $0.23 Estimate, Sales $92M-$97M vs $90.37M Est.",2018-11-09 07:36:00-05:00,SRDX,neutral
1179170.0,"SurModics, Inc. Q4 EPS $0.05 Beats $(0.03) Estimate, Sales $23.038M Beat $21.56M Estimate",2018-11-09 07:36:00-05:00,SRDX,neutral
1179171.0,"The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall",2018-11-09 07:32:00-05:00,SRDX,neutral
1179172.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,SRDX,neutral
1179173.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,SRDX,neutral
1179174.0,"Stocks Which Set New 52-Week High Friday, August 31",2018-09-04 10:29:00-04:00,SRDX,neutral
1179175.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,SRDX,neutral
1179176.0,"The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage",2018-08-31 08:29:00-04:00,SRDX,positive
1179177.0,"Stocks Which Set New 52-Week High Yesterday, August 28th",2018-08-29 11:13:00-04:00,SRDX,neutral
1179178.0,"Stocks Which Set New 52-Week High Yesterday, August 23rd",2018-08-24 09:11:00-04:00,SRDX,neutral
1179179.0,"The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict",2018-08-24 08:47:00-04:00,SRDX,positive
1179180.0,"Stocks Which Set New 52-Week High Yesterday, August 22nd",2018-08-23 10:51:00-04:00,SRDX,neutral
1179181.0,"Stocks Which Set New 52-Week High Yesterday, August 16th",2018-08-17 10:39:00-04:00,SRDX,neutral
1179182.0,"Stocks Which Set New 52-Week High Yesterday, August 15th",2018-08-16 10:22:00-04:00,SRDX,neutral
1179183.0,"Stocks Which Set New 52-Week High Yesterday, August 14th",2018-08-15 12:29:00-04:00,SRDX,neutral
1179184.0,"The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue",2018-08-15 08:48:00-04:00,SRDX,negative
1179185.0,"The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut",2018-08-14 08:23:00-04:00,SRDX,neutral
1179186.0,"Stocks Which Set New 52-Week High Yesterday, August 9th",2018-08-10 10:03:00-04:00,SRDX,neutral
1179187.0,"Stocks Which Set New 52-Week High Yesterday, August 8th",2018-08-09 11:03:00-04:00,SRDX,neutral
1179188.0,"The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings",2018-08-09 08:39:00-04:00,SRDX,positive
1179189.0,"Stocks Which Set New 52-Week High Yesterday, August 6th",2018-08-07 11:27:00-04:00,SRDX,neutral
1179190.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,SRDX,negative
1179191.0,52 Biggest Movers From Yesterday,2018-08-07 05:19:00-04:00,SRDX,neutral
1179192.0,Surmodics shares are trading up 10.5% after the company beat Q2 sales estimates and raised 2018 sales guidance.,2018-08-06 14:33:00-04:00,SRDX,positive
1179193.0,44 Stocks Moving In Monday's Mid-Day Session,2018-08-06 12:39:00-04:00,SRDX,neutral
1179194.0,Surmodics Raises FY18 Sales Outlook From $75M-$79M To $79M-$81M vs $76.8M Est.,2018-08-06 07:32:00-04:00,SRDX,neutral
1179195.0,"SurModics Q3 EPS $0.27 May Not Compare To $(0.24) Estimate, Sales $22.2M Beat $19.38M Estimate",2018-08-06 07:30:00-04:00,SRDX,neutral
1179196.0,"Stocks Which Set New 52-Week High Yesterday, July 26th:",2018-07-27 10:42:00-04:00,SRDX,neutral
1179197.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,SRDX,neutral
1179198.0,"Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering",2018-07-24 08:53:00-04:00,SRDX,positive
1179199.0,Stocks Which Set New 52-Week Highs Friday,2018-07-23 11:08:00-04:00,SRDX,neutral
1179200.0,Stocks Which Set New 52-Week High Yesterday,2018-07-20 09:05:00-04:00,SRDX,neutral
1179201.0,"Benzinga's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To Offer Shares, Intuitive Surgical's Strong Q2",2018-07-20 07:53:00-04:00,SRDX,positive
1179202.0,"Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index",2018-07-05 07:43:00-04:00,SRDX,neutral
1179203.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,SRDX,neutral
1179204.0,"Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate",2018-06-12 08:47:00-04:00,SRDX,positive
1179205.0,Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO,2018-06-01 08:16:00-04:00,SRDX,neutral
1179206.0,"Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time",2018-05-31 08:22:00-04:00,SRDX,positive
1179207.0,"Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA",2018-05-30 08:14:00-04:00,SRDX,positive
1179208.0,"Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings",2018-05-24 08:37:00-04:00,SRDX,neutral
1179209.0,"Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More",2018-05-17 08:27:00-04:00,SRDX,neutral
1179210.0,Surmodics Reports CFO Andrew LaFrence Resigned; Timothy Arens Named As Interim Replacement,2018-05-16 16:11:00-04:00,SRDX,negative
1179211.0,"Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway",2018-05-15 08:44:00-04:00,SRDX,positive
1179212.0,"Surmodics Reports Purchase Of Thrombectomy Technology Assets From Embolitech For $5M In Upfront Payment, Added Undetermined Amounts Related To Regulatory Milestones",2018-05-14 08:30:00-04:00,SRDX,positive
1179213.0,"Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway",2018-05-09 07:48:00-04:00,SRDX,neutral
1179214.0,Surmodics Raises FY2018 EPS Guidance from $(0.20)-0.05 to $(0.06)-0.09 vs $(0.11) Est; Raises FY2018 Sales Guidance from $72.0M-75.0M to $75.0M-79.0M vs $73.80M Est,2018-05-02 07:45:00-04:00,SRDX,neutral
1179215.0,"SurModics Q2 EPS $0.15 Beats $(0.08) Estimate, Sales $19.058M Beat $17.71M Estimate",2018-05-02 07:44:00-04:00,SRDX,neutral
1179216.0,"Surmodics Reports FDA Clearance For New 0.18"" Low-Profile PTA Balloon Dilation Catheter",2018-04-23 08:30:00-04:00,SRDX,neutral
1179217.0,Mid-Morning Market Update: Markets Mostly Higher; Ciena Profit Tops Expectations,2018-03-06 10:23:00-05:00,SRDX,positive
1179218.0,"Benzinga's Top Upgrades, Downgrades For February 28, 2018",2018-02-28 09:11:00-05:00,SRDX,positive
1179219.0,Barrington Research Upgrades Surmodics to Outperform,2018-02-28 08:59:00-05:00,SRDX,neutral
1179220.0,"Needham Initiates Coverage On Surmodics with Buy Rating, Announces $42.00 Price Target",2018-02-28 07:30:00-05:00,SRDX,neutral
1179221.0,42 Biggest Movers From Yesterday,2018-02-28 04:49:00-05:00,SRDX,neutral
1179222.0,35 Stocks Moving In Tuesday's Mid-Day Session,2018-02-27 12:32:00-05:00,SRDX,neutral
1179223.0,"Abbott, Surmodics Announce Agreement for Next-Generation Drug-Coated Balloon; Abbott To Receive Exclusive Worldwide Commercialization Rights For SurVeil",2018-02-27 09:06:00-05:00,SRDX,positive
1179224.0,"Surmodics Sees FY18 Adj. EPS $(0.20)-$0.05 vs $(0.36) Est., Sale $72M-$75M vs $73.9M Est.",2018-02-08 07:34:00-05:00,SRDX,neutral
1179225.0,"Surmodics Reports Q1 Adj. EPS $0.10 vs $0.19 In Same Qtr. Last Year, Sales $17M vs $17.8M YoY",2018-02-08 07:34:00-05:00,SRDX,neutral
1179226.0,Surmodics Receives 510(K) Clearance for Telemark Coronary/Peripheral Support Microcatheter from the U.S. Food and Drug Administration,2018-01-22 08:21:00-05:00,SRDX,positive
1179227.0,"Surmodics Sees FY18 Adj. EPS $(0.41)-$(0.16), Sales $72M-$75M vs $73.8M Est.",2017-11-08 07:41:00-05:00,SRDX,neutral
1179228.0,"Surmodics Reports Q4 Adj. EPS $0.18 May Not Compare To $(0.01) Est., Sales $20.1M vs $17M Est.",2017-11-08 07:40:00-05:00,SRDX,neutral
1179229.0,Companies Holding Analyst/Investor Days Today Include Abiomed and Surmodics,2017-10-31 09:02:00-04:00,SRDX,neutral
1179230.0,"Surmodics Raises FY17 Outlook: Sales $65M-$68M TO $70M-$72M vs $67.5M Est., Adj. EPS From $0.15-$0.25 To $0.29-$0.39 vs $0.19 Est.",2017-08-03 07:56:00-04:00,SRDX,neutral
1179231.0,"Surmodics Reports Q3 Adj. EPS $0.09, Sales $17.8M vs $16M Est.",2017-08-03 07:55:00-04:00,SRDX,neutral
1179232.0,"Lake Street Initiates Coverage On Surmodics with Buy Rating, Announces $40.00 Price Target",2017-07-14 08:56:00-04:00,SRDX,neutral
1179233.0,15 Biggest Mid-Day Gainers For Tuesday,2017-06-27 12:31:00-04:00,SRDX,neutral
1179234.0,Mid-Morning Market Update: Markets Open Lower; EU Slaps Google Parent Alphabet With $2.7 Billion Fine,2017-06-27 10:23:00-04:00,SRDX,negative
1179235.0,"Benzinga's Top Upgrades, Downgrades For June 27, 2017",2017-06-27 09:27:00-04:00,SRDX,positive
1179236.0,"Aegis Capital Initiates Coverage On Surmodics with Buy Rating, Announces $43.50 Price Target",2017-06-27 06:22:00-04:00,SRDX,neutral
1179237.0,"Surmodics Narrows FY17 Sales Outlook from $64M-$68M to $65M-$68M, Cuts Adj. EPS Guidance from $0.18-$0.33 to $0.15-$0.25",2017-04-27 07:58:00-04:00,SRDX,negative
1179238.0,"Surmodics Reports Q2 Adj. EPS $0.05 vs $0.07 Est., Sales $17.5M vs $16.2M Est.",2017-04-27 07:57:00-04:00,SRDX,neutral
1179239.0,Why Is Surmodics (SRDX) Down 2.7% Since the Last Earnings Report?,2017-03-08 10:01:00-05:00,SRDX,neutral
1179240.0,"UPDATE: Surmodics Raises FY17 Outlook: Adj. EPS from $0.15-$0.35 to $0.18-$0.33 vs $0.24 Est., GAAP Sales from $63M-$67M to $64M-$68M vs $65.3M Est.",2017-02-02 07:37:00-05:00,SRDX,neutral
1179241.0,Surmodics Raises Outlook,2017-02-02 07:36:00-05:00,SRDX,neutral
1179242.0,"Surmodics Reports Q1 Adj. EPS $0.19 vs $0.09 Est., Sales $17.8M vs $15.8M Est.",2017-02-02 07:36:00-05:00,SRDX,neutral
1179243.0,Barrington Research Downgrades Surmodics to Market Perform,2016-11-21 08:59:00-05:00,SRDX,neutral
1179244.0,Canaccord Genuity Medical Technology And Diagnostics Forum Today,2016-11-17 09:56:00-05:00,SRDX,neutral
1179245.0,"Surmodics Sees FY17 Adj. EPS $0.15-$0.35, GAAP Sales $63M-$67M vs $69.3M Est.",2016-11-16 07:31:00-05:00,SRDX,neutral
1179246.0,"Surmodics Reports Q4 Adj. EPS $0.26 vs $0.34 in Same Qtr. Last Year, Sales $18.2M vs $16M Est.",2016-11-16 07:30:00-05:00,SRDX,neutral
1179247.0,"Earnings Scheduled For November 16, 2016",2016-11-16 04:29:00-05:00,SRDX,neutral
1179248.0,Surmodics IVD Launches Breakthrough StabilBlock Immunoassay Stabilizer,2016-08-01 07:07:00-04:00,SRDX,neutral
1179249.0,"Surmodics Reports Q3 EPS $0.37 Does Not Compare To Est. $0.12, Rev. $20M vs. Est. $16.3M",2016-07-28 07:34:00-04:00,SRDX,neutral
1179250.0,"Upcoming Non-Deal Road Shows For Syntel, Franklin Covey And Others",2016-07-12 14:16:00-04:00,SRDX,neutral
1179251.0,"Surmodics Reports Q2 Cont. Ops EPS $0.06, Non GAAP EPS $0.20, Sales $16.7M Vs est $15.13M",2016-05-02 16:51:00-04:00,SRDX,neutral
1179252.0,SurModics Reports First Patient Enrolled in IDE Study of SurVeil Drug-Coated Balloon,2016-04-06 08:13:00-04:00,SRDX,neutral
1179253.0,SurModics Reports Initial Patient Enrolled in IDE Study of SurVeil Drug-Coated Balloon,2016-04-06 08:07:00-04:00,SRDX,neutral
1179254.0,"SurModics Reports Q1 EPS $0.38 vs. Est. $0.17, Rev. $16.5M vs. Est. $14.58M",2016-01-28 07:37:00-05:00,SRDX,neutral
1179255.0,SurModics Sees FY2016 Sales $62.0M-66.0M vs $59.55M Est,2016-01-11 08:16:00-05:00,SRDX,neutral
1179256.0,Surmodics Announces Acquisition of Normedix for $14M,2016-01-11 08:14:00-05:00,SRDX,neutral
1179257.0,UPDATE: SurModics Sees FY16 GAAP Sales $60M-$64M vs $63M Est.,2016-01-08 07:34:00-05:00,SRDX,neutral
1179258.0,SurModics Sees FY16 Adj. EPS $0.66-$0.75 vs $0.73 Est.,2016-01-08 07:30:00-05:00,SRDX,neutral
1179259.0,"SurModics Raises Buyback Plan to $30M; Sees FY16 GAAP EPS $0.70-$0.80, Sales $56M-$60M vs $59.8M Est.",2015-11-10 07:35:00-05:00,SRDX,neutral
1179260.0,"SurModics Reports Q4 EPS $0.22 Vs Est $0.19, Sales $17.4M Vs Est $15.30M",2015-11-10 07:35:00-05:00,SRDX,neutral
1179261.0,SurModics Receives FDA IDE Approval for Early Feasibility Study of the SurVeil™ Drug-Coated Balloon,2015-10-05 08:00:00-04:00,SRDX,positive
1179262.0,Top 4 Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2015-09-16 04:09:00-04:00,SRDX,negative
1179263.0,"SurModic Reports Q3 EPS $0.30 Vs Est $0.21, Sales $15.9M vs Est $14.87M; Raises FY EPS To $0.95-$1.00 Vs Est $0.89 & Revs Up To $58M-$60M Vs Est $58.69M",2015-08-05 07:38:00-04:00,SRDX,neutral
1179264.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Operating Margin,2015-06-23 05:01:00-04:00,SRDX,positive
1179265.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS,2015-06-08 04:14:00-04:00,SRDX,positive
1179266.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROA,2015-05-05 04:51:00-04:00,SRDX,positive
1179267.0,"SurModic Reports Q2 EPS $0.23 Vs Est $0.23, Sales $14.4M Vs Est $13.97M",2015-04-30 16:12:00-04:00,SRDX,neutral
1179268.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest EPS,2015-02-12 04:23:00-05:00,SRDX,positive
1179269.0,"SurModics Reports Q1 EPS $0.27 Vs Est $0.21, Revs $14.2M Vs Est $14.29M",2015-01-29 16:25:00-05:00,SRDX,neutral
1179270.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROI,2015-01-22 04:20:00-05:00,SRDX,positive
1179271.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2014-12-31 04:25:00-05:00,SRDX,negative
1179272.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI,2014-12-18 04:44:00-05:00,SRDX,positive
1179273.0,"Barrington Research Assumes SurModics, Inc. at Outperform, Maintains $28.00 PT",2014-12-15 08:25:00-05:00,SRDX,neutral
1179274.0,SurModics Announces $20M Accelerated Share Repurchase Program,2014-11-12 08:06:00-05:00,SRDX,positive
1179275.0,"SurModics, Inc. Sees FY2015 ADJ. EPS $0.85-0.95",2014-11-06 16:30:00-05:00,SRDX,neutral
1179276.0,"SurModics, Inc. Reports Q4 EPS of $0.26 vs $0.25 Est; Revenue of $15.30M vs $14.92M Est",2014-11-06 16:21:00-05:00,SRDX,neutral
1179277.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS,2014-10-08 04:49:00-04:00,SRDX,positive
1179278.0,Morning Market Movers ,2014-08-01 09:41:00-04:00,SRDX,neutral
1179279.0,"SurModics, Inc. Sees FY2014 EPS $0.90-0.97; Sees Sales $56.0M-58.50M",2014-07-31 16:30:00-04:00,SRDX,neutral
1179280.0,"SurModics, Inc. Reports Q2 EPS of $0.26 vs $0.23 Est; Revenue of $14.60M vs $14.84M Est",2014-07-31 16:30:00-04:00,SRDX,neutral
1179281.0,S-3 Filing from Surmodics Shows Registration for $175M Mixed Securities Shelf Offering,2014-07-31 14:34:00-04:00,SRDX,positive
1179282.0,Stocks Hitting 52-Week Lows,2014-07-28 10:26:00-04:00,SRDX,negative
1179283.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI,2014-07-14 04:55:00-04:00,SRDX,positive
1179284.0,"SurModics, Inc. Lowers FY2014 Sales Guidance from $58.0M-62.0M to $56.0M-58.50M vs $59.30M Est",2014-05-01 16:50:00-04:00,SRDX,negative
1179285.0,"SurModics, Inc. Reports Q2 EPS of $0.22 vs $0.20 Est; Reaffirms Outlook",2014-05-01 16:49:00-04:00,SRDX,neutral
1179286.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest EPS,2014-04-23 04:43:00-04:00,SRDX,positive
1179287.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROA,2014-04-11 04:41:00-04:00,SRDX,positive
1179288.0,Benzinga's Top Initiations,2014-04-04 07:33:00-04:00,SRDX,positive
1179289.0,"Benchmark Initiates Coverage on SurModics, Inc. at Buy, Announces $30.00 PT",2014-04-04 07:10:00-04:00,SRDX,neutral
1179290.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates,2014-03-20 04:29:00-04:00,SRDX,positive
1179291.0,"Laidlaw & Co. Initiates Coverage on SurModics, Inc. at Buy, Announces $30.00 PT",2014-02-25 10:44:00-05:00,SRDX,neutral
1179292.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2014-02-13 04:18:00-05:00,SRDX,negative
1179293.0,"SurModics, Inc. Reports Q4 EPS of $0.21, Inline; Revenue of $13.90M vs $14.15M Est",2014-01-30 16:00:00-05:00,SRDX,neutral
1179294.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS,2014-01-15 04:10:00-05:00,SRDX,positive
1179295.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest ROA,2013-12-30 06:12:00-05:00,SRDX,positive
1179296.0,SurModics Affirms FY14 Outlook,2013-12-11 14:22:00-05:00,SRDX,neutral
1179297.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Operating Margin,2013-11-06 05:20:00-05:00,SRDX,positive
1179298.0,"SurModics, Inc. Sees FY2014 EPS $0.80-0.92 vs $0.93 Est; Sees Sales $58.0M-62.0M vs $62.52M Est",2013-11-05 17:13:00-05:00,SRDX,neutral
1179299.0,"SurModics, Inc. Reports Q4 EPS of $0.26 vs $0.22 Est; Revenue of $14.30M vs $14.82M Est",2013-11-05 17:12:00-05:00,SRDX,neutral
1179300.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2013-11-01 04:26:00-04:00,SRDX,negative
1179301.0,How to Profit from the Expected Obamacare Rally,2013-10-22 09:21:00-04:00,SRDX,positive
1179302.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2013-10-01 03:17:00-04:00,SRDX,negative
1179303.0,"Shares of Bioscrips Spike into Positive Territory Following Positive Mention on CNBC, Shares of SurModics Also Moving",2013-09-25 12:45:00-04:00,SRDX,positive
1179304.0,"SurModics Reports Organizational Changes, Cutting 7 Jobs, 6% of Staff, Expecting Q4 Charge of $0.02/Share",2013-09-03 16:31:00-04:00,SRDX,negative
1179305.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2013-08-19 04:10:00-04:00,SRDX,negative
1179306.0,UPDATE: Barrington Research Upgrades SurModics on Stable Cash Flow,2013-08-05 16:07:00-04:00,SRDX,positive
1179307.0,"Barrington Research Upgrades SurModics, Inc. to Outperform, Announces $27.00 PT",2013-08-05 15:55:00-04:00,SRDX,neutral
1179308.0,"Form 8-K from Surmodics, SRI Shows Settlement to Resolve Litigation",2013-08-02 14:18:00-04:00,SRDX,positive
1179309.0,"Feltl & Co. Upgrades SurModics, Inc. to Strong Buy",2013-08-01 09:42:00-04:00,SRDX,positive
1179310.0,"SurModics, Inc. Reports Q2 EPS of $0.21, Inline; Revenue of $14.30M vs $15.03M Est",2013-07-31 17:01:00-04:00,SRDX,neutral
1179311.0,Afternoon Market Losers,2013-05-30 14:30:00-04:00,SRDX,negative
1179312.0,"SurModics, Inc. Reports Q2 EPS of $0.28 vs $0.21 Est; Revenue of $13.70M vs $13.92M Est",2013-05-07 16:06:00-04:00,SRDX,neutral
1179313.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2013-04-30 04:19:00-04:00,SRDX,negative
1179314.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Operating Margin,2013-04-18 06:01:00-04:00,SRDX,positive
1179315.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates For The Next Quarter,2013-02-21 04:21:00-05:00,SRDX,positive
1179316.0,SurModics Authorizes $10M Buyback Plan,2013-01-30 16:24:00-05:00,SRDX,neutral
1179317.0,"SurModics, Inc. Sees FY2013 EPS $0.86-0.99 vs $0.82 Est",2013-01-30 16:24:00-05:00,SRDX,neutral
1179318.0,"SurModics, Inc. Reports Q1 EPS of $0.29 vs $0.18 Est; Revenue of $13.85M vs $13.63M Est",2013-01-30 16:04:00-05:00,SRDX,neutral
1179319.0,"Barrington Research Downgrades SurModics, Inc. to Market Perform",2013-01-25 15:58:00-05:00,SRDX,neutral
1179320.0,SurModics Names Andy Lafrence CFO,2012-12-21 16:01:00-05:00,SRDX,neutral
1179321.0,"Barrington Research Maintains SurModics at Outperform, Raises PT from $20 to $22",2012-11-12 07:06:00-05:00,SRDX,neutral
1179322.0,"Feltl and Company Maintains SurModics at Buy, Raises PT from $20 to $21.50",2012-11-07 11:42:00-05:00,SRDX,neutral
1179323.0,"SurModics Guides FY13 Sales $55-58M vs $56.64M Est, EPS $0.75-0.87 vs $0.81 Est",2012-11-06 16:13:00-05:00,SRDX,neutral
1179324.0,SurModics Reports Q4 EPS $0.19 vs $0.13 Est; Revenues $13.8M vs $12.39M Est,2012-11-06 16:07:00-05:00,SRDX,neutral
1179325.0,Stocks Hitting 52-Week Highs,2012-10-03 10:03:00-04:00,SRDX,neutral
1179326.0,Surmodics Accepted 2.89M Shares at $19 a Piece ,2012-09-11 08:47:00-04:00,SRDX,positive
1179327.0,Surmodics Announces Buyback of 2.89M Shares At $19 Each,2012-09-06 08:04:00-04:00,SRDX,positive
1179328.0,SurModics Announces Resignation of Jeffrey Smith from the Board of Directors,2012-08-27 16:31:00-04:00,SRDX,negative
1179329.0,"Benzinga'a M&A Chatter for Monday August 6, 2012",2012-08-06 17:27:00-04:00,SRDX,neutral
1179330.0,"UPDATE: Barrington Research Reiterates Outperform Rating, Raises PT on SurModics",2012-08-06 09:57:00-04:00,SRDX,neutral
1179331.0,SurModics Announces Commencement of Tender Offer to Purchase up to $55 Million of Its Common Stock,2012-08-06 09:54:00-04:00,SRDX,neutral
1179332.0,SurModics Commences Tender Offer to Acquire $65M of Its Common Stock,2012-08-06 08:02:00-04:00,SRDX,neutral
1179333.0,"Barrington Research Maintains SurModics at Outperform, Raises PT from $18 to $20",2012-08-06 05:47:00-04:00,SRDX,neutral
1179334.0,"Feltl and Company Upgrades SurModics from Hold to Buy, Raises PT from $15 to $20",2012-08-02 09:00:00-04:00,SRDX,neutral
1179335.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Cash,2012-08-02 01:05:00-04:00,SRDX,positive
1179336.0,SurModics Reports Q3 EPS $0.18 vs $0.13 Est; Revenues $14M vs $12.39M Est,2012-08-01 16:24:00-04:00,SRDX,neutral
1179337.0,SurModics Halted Pending News,2012-08-01 16:06:00-04:00,SRDX,neutral
1179338.0,Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest Cash,2012-07-13 02:47:00-04:00,SRDX,positive
1179339.0,SurModics Reports Q2 EPS $0.14 vs $0.12 Est; Revenues $12.2M vs $12.30M Est,2012-05-08 16:19:00-04:00,SRDX,neutral
1179340.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2012-03-30 05:16:00-04:00,SRDX,negative
1179341.0,Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Lowest PEG Ratio,2012-02-13 05:07:00-05:00,SRDX,negative
1179342.0,Surmodics Files to Delay 10-Q Filing,2012-02-10 16:04:00-05:00,SRDX,negative
1179343.0,Barrington Research Maintains SurModics Outperform,2012-02-06 15:18:00-05:00,SRDX,neutral
1179344.0,From Earlier: SurModics Sees Q1 EPS of $0.12 vs $0.11 Est ,2012-02-03 07:00:00-05:00,SRDX,neutral
1179345.0,Barrington Research Reiterates Outperform on SurModics; PT $18,2011-11-07 11:13:00-05:00,SRDX,neutral
1179346.0,"Feltl & Company Upgrades SurModics to Buy, $13 PT",2011-11-02 10:16:00-04:00,SRDX,neutral
1179347.0,SurModics Announces Agreement to Sell Pharmaceutical Assets for $30M,2011-11-02 06:49:00-04:00,SRDX,positive
1179348.0,"Surmodics Cutting 9% of Workforce, Including CFO Ankeny",2011-08-23 16:54:00-04:00,SRDX,negative
1179349.0,"NASDAQ Top Percentage Gainers: Web.com, SurModics, Air Transport Group, Insight Enterprises",2011-08-05 14:08:00-04:00,SRDX,positive
1179350.0,SurModics Comments on Johnson & Johnson Announcement; Reaffirms 2011 Guidance ,2011-06-15 15:26:00-04:00,SRDX,neutral
1179351.0,Gainers on Thursday to Watch on Friday,2011-04-28 12:09:00-04:00,SRDX,neutral
1179352.0,"SRDX Beats on EPS, Sales Slip - Analyst Blog",2011-01-28 13:31:00-05:00,SRDX,neutral
1179353.0,"SRDX Beats on EPS, Sales Slip - Analyst Blog",2011-01-28 13:00:00-05:00,SRDX,neutral
1179354.0,SurModics Upped to Neutral - Analyst Blog,2011-01-18 16:01:00-05:00,SRDX,neutral
1179355.0,SurModics Upped to Neutral - Analyst Blog,2011-01-18 15:43:00-05:00,SRDX,neutral
1179356.0,SurModics May Drop Pharma Unit - Analyst Blog,2010-12-15 15:33:00-05:00,SRDX,negative
1179357.0,SurModics May Drop Pharma Unit - Analyst Blog,2010-12-15 15:06:00-05:00,SRDX,negative
1179358.0,"SurModics May Sell Business Unit, Shares Surge 14.4% (SRDX)",2010-12-15 12:48:00-05:00,SRDX,positive
1179359.0,"Top Performing Industries For December 15 (CTRP, RF, SRDX, NWL)",2010-12-15 10:21:00-05:00,SRDX,positive
1179360.0,SurModics Trading Substantially Higher Today,2010-12-15 10:20:00-05:00,SRDX,neutral
1179361.0,"SurModics Names Gary R. Maharaj President, CEO",2010-12-14 16:35:00-05:00,SRDX,neutral
1179362.0,SurModics to Explore Strategic Alternatives for its Pharmaceuticals Business ,2010-12-14 16:33:00-05:00,SRDX,neutral
1179363.0,"Options Brief: SurModics, Inc. (SRDX)",2010-12-10 12:35:00-05:00,SRDX,neutral
1179364.0,"SurModics, Inc. (SRDX) - Bear of the Day",2010-12-02 02:03:00-05:00,SRDX,neutral
1179365.0,"SurModics, Inc. (SRDX) - Bear of the Day",2010-12-01 19:00:00-05:00,SRDX,neutral
1179366.0,SurModics Cut to Underperform - Analyst Blog,2010-12-01 14:51:00-05:00,SRDX,negative
1179367.0,SurModics Cut to Underperform - Analyst Blog,2010-12-01 08:58:00-05:00,SRDX,negative
1179368.0,Ramius Reports 12% Ownership In SurModics ,2010-11-17 08:26:00-05:00,SRDX,neutral
1179369.0,SurModics Disappoints in Q4 - Analyst Blog,2010-11-12 15:03:00-05:00,SRDX,negative
1179370.0,"SurModics Getting Killed, Down 27% (SRDX)",2010-11-11 12:35:00-05:00,SRDX,negative
1179371.0,"Some Ugly Issues This Morning (ANW, RST, SRDX)",2010-11-11 10:16:00-05:00,SRDX,negative
1179372.0,SurModics Falls 22% After Hours ( SRDX),2010-11-10 16:41:00-05:00,SRDX,neutral
1179373.0,SurModics Reports Fourth Quarter and Fiscal Year 2010 Results: Loss Per Share of $0.05,2010-11-10 16:04:00-05:00,SRDX,neutral
1179374.0,SurModics Announces New Board Director,2010-09-21 16:03:00-04:00,SRDX,neutral
1179375.0,SurModics Stays Neutral - Analyst Blog,2010-09-13 16:36:00-04:00,SRDX,neutral
1179376.0,SurModics Falls Short - Analyst Blog,2010-08-04 18:33:00-04:00,SRDX,neutral
1179377.0,"Benzinga’s Top Upgrades (CEPH, ENR, SRDX, DY)",2010-08-03 08:11:00-04:00,SRDX,positive
1179378.0,Barrington Upgrades SRDX To Market Perform,2010-08-03 07:23:00-04:00,SRDX,neutral
1179379.0,"Today's Morning Top Gainers (FONR, AVCT, ICTG, KGN, SRDX)",2009-10-06 11:50:00-04:00,SRDX,positive
